Fc Engineered Anti-Human TNF Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ20] (CAT#: BioBet-C020ZP) Datasheet

Target
TNF
Isotype
Whole Human Antibody
Description
CDC-enhanced Adalimumabis a Fc-modified anti-TNF therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Adalimumab, the Fc region of Adalimumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Crohn's disease
Ulcerative colitis
Plaque psoriasis
Hidradenitis suppurativa
Juvenile idiopathic arthritis
Classification
Therapeutic antibody; biobetter
Patent
Blinatumomab was first received FDA approval in 2002. The patent expired in the United States in 2016.
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Adalimumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNF
Full Name
tumor necrosis factor
Background
This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine.
Alternative Names
DIF; TNFA; TNFSF2; TNLG1F; TNF-alpha
Gene ID
UniProt ID
Trade name
Humira, Mabura, Exemptia, others
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB00051 (BTD00049, BIOD00049)
CAS number
331731-18-1
Antibody Isotype
Human IgG1
Description
Adalimumab is an antibody therapeutic for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, purulent urethritis, uveitis, and Juvenile idiopathic arthritis. It is used by subcutaneous injection to target tumor necrosis factor. Adalimumab was originally launched by Abbvie in the United States and was approved by the FDA in 2002. It is called Humira. It is produced by recombinant DNA technology using mammalian cell expression systems.
Indication
Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Crohn's disease
Ulcerative colitis
Plaque psoriasis
Hidradenitis suppurativa
Juvenile idiopathic arthritis
Synonyms
adalimumab-adbm, adalimumab-bwwd, adalimumab-afzb, adalimumab-atto
UNII
FYS6T7F842

TNF is a naturally occurring cytokine that plays a role in normal inflammation and immune responses. Elevated levels of TNF are found in the synovial fluid of patients with rheumatoid arthritis, psoriasis arthritis, and ankylosing spondylitis, and play an essential role in pathological inflammation and inflammation.
Adalimumab specifically binds tumor necrosis factor-α (TNF-alpha) 2, 3, and inhibits its interaction with TNF receptors on the cell surface. Studies have shown that Fc-mediated apoptosis has been shown to be most potently induced by adalimumab. Therefore, adalimumab can simultaneously induce both CDC and ADCC effects to exert therapeutic functions.

Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Crohn's disease
Ulcerative colitis
Plaque psoriasis
Hidradenitis suppurativa
Juvenile idiopathic arthritis

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK